Log In
BCIQ
Print this Print this
 

Bilaxten, bilastine (TAC-202)

  Manage Alerts
Collapse Summary General Information
Company Faes Farma S.A.
DescriptionHistamine H1 receptor (HRH1) antagonist
Molecular Target Histamine H1 receptor (HRH1)
Mechanism of ActionHistamine H1 receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationAllergy
Indication DetailsTreat allergic rhinitis; Treat allergic rhinitis, urticaria and itching resulting from skin diseases
Regulatory Designation
PartnerAralez Pharmaceuticals Inc.;
Laboratoires Pierre Fabre S.A.;
Meiji Seika Pharma Co. Ltd.;
Menarini Group;
Taiho Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

4

$146.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today